Laboratory Corporation of America Holdings Logo

Laboratory Corporation of America Holdings

LH

(1.5)
Stock Price

235,21 USD

6.28% ROA

5.67% ROE

39.79x PER

Market Cap.

17.855.635.378,00 USD

65.65% DER

1.69% Yield

3.6% NPM

Laboratory Corporation of America Holdings Stock Analysis

Laboratory Corporation of America Holdings Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Laboratory Corporation of America Holdings Fundamental Stock Analysis
# Analysis Rating
1 ROE

ROE in an average range (7.13%) suggests satisfactory profitability and decent utilization of shareholders' equity.

2 ROA

The stock's ROA (9.08%) indicates that it's doing well in making money from the things it owns. This makes it a good option to invest and make consistent profits.

3 PBV

The stock's PBV ratio (2.33x) indicates a justifiable valuation, presenting a compelling choice for investors seeking reasonable returns.

4 DER

The stock has a reasonable amount of debt compared to its ownership (80%), suggesting a balanced financial position and a moderate level of risk.

5 Dividend Growth

The company's dividend growth has been consistently strong over the past three years, with annual increases that demonstrate its commitment to rewarding shareholders.

6 Buffet Intrinsic Value

The company's stock presents an enticing opportunity as it appears undervalued (5.000) by Warren Buffett's formula, indicating that its intrinsic value exceeds the market price.

7 Revenue Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

8 Net Profit Growth

This company's net profit has remained flat over the past five years, suggesting a lack of growth and making it a less attractive investment opportunity.

9 Assets Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

10 Graham Number

Based on the Graham number, this company's stock price appears to be higher than its intrinsic value, signaling a potentially unfavorable investment choice.

11 Dividend

The company's lack of dividends in the past three years may concern investors seeking regular income.

Laboratory Corporation of America Holdings Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Laboratory Corporation of America Holdings Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

Laboratory Corporation of America Holdings Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Laboratory Corporation of America Holdings Revenue
Year Revenue Growth
1988 313.900.000
1989 402.400.000 21.99%
1990 501.900.000 19.82%
1991 603.900.000 16.89%
1992 721.400.000 16.29%
1993 760.500.000 5.14%
1994 872.500.000 12.84%
1995 1.432.000.000 39.07%
1996 1.607.700.000 10.93%
1997 1.519.000.000 -5.84%
1998 1.612.600.000 5.8%
1999 1.698.700.000 5.07%
2000 1.919.300.000 11.49%
2001 2.199.800.000 12.75%
2002 2.507.700.000 12.28%
2003 2.939.400.000 14.69%
2004 3.084.800.000 4.71%
2005 3.327.600.000 7.3%
2006 3.590.800.000 7.33%
2007 4.068.200.000 11.73%
2008 4.505.200.000 9.7%
2009 4.694.700.000 4.04%
2010 5.003.900.000 6.18%
2011 5.542.300.000 9.71%
2012 5.671.400.000 2.28%
2013 5.808.300.000 2.36%
2014 6.011.600.000 3.38%
2015 8.680.100.000 30.74%
2016 9.641.800.000 9.97%
2017 10.441.400.000 7.66%
2018 11.333.400.000 7.87%
2019 11.554.800.000 1.92%
2020 13.978.500.000 17.34%
2021 16.120.900.000 13.29%
2022 14.876.800.000 -8.36%
2023 12.227.200.000 -21.67%
2023 12.161.600.000 -0.54%
2024 12.883.600.000 5.6%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Laboratory Corporation of America Holdings Research and Development Expenses
Year Research and Development Expenses Growth
1988 0
1989 0 0%
1990 0 0%
1991 0 0%
1992 0 0%
1993 0 0%
1994 0 0%
1995 0 0%
1996 0 0%
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 2.000.000 100%
2024 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Laboratory Corporation of America Holdings General and Administrative Expenses
Year General and Administrative Expenses Growth
1988 0
1989 0 0%
1990 0 0%
1991 0 0%
1992 0 0%
1993 0 0%
1994 149.300.000 100%
1995 313.500.000 52.38%
1996 490.000.000 36.02%
1997 499.900.000 1.98%
1998 405.000.000 -23.43%
1999 448.200.000 9.64%
2000 483.000.000 7.2%
2001 516.500.000 6.49%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Laboratory Corporation of America Holdings EBITDA
Year EBITDA Growth
1988 313.900.000
1989 131.100.000 -139.44%
1990 162.100.000 19.12%
1991 199.700.000 18.83%
1992 360.800.000 44.65%
1993 201.200.000 -79.32%
1994 174.300.000 -15.43%
1995 138.200.000 -26.12%
1996 9.500.000 -1354.74%
1997 -7.600.000 225%
1998 209.200.000 103.63%
1999 236.800.000 11.66%
2000 343.700.000 31.1%
2001 479.900.000 28.38%
2002 572.400.000 16.16%
2003 668.400.000 14.36%
2004 733.700.000 8.9%
2005 803.000.000 8.63%
2006 849.200.000 5.44%
2007 1.037.000.000 18.11%
2008 904.400.000 -14.66%
2009 1.027.400.000 11.97%
2010 1.075.200.000 4.45%
2011 1.125.900.000 4.5%
2012 1.149.300.000 2.04%
2013 1.113.400.000 -3.22%
2014 1.198.400.000 7.09%
2015 1.576.800.000 24%
2016 1.880.500.000 16.15%
2017 1.972.000.000 4.64%
2018 2.105.200.000 6.33%
2019 1.968.600.000 -6.94%
2020 3.543.600.000 44.45%
2021 4.116.700.000 13.92%
2022 2.743.200.000 -50.07%
2023 1.746.800.000 -57.04%
2023 1.704.600.000 -2.48%
2024 1.853.200.000 8.02%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Laboratory Corporation of America Holdings Gross Profit
Year Gross Profit Growth
1988 313.900.000
1989 191.100.000 -64.26%
1990 241.000.000 20.71%
1991 293.400.000 17.86%
1992 344.900.000 14.93%
1993 339.100.000 -1.71%
1994 303.600.000 -11.69%
1995 453.100.000 32.99%
1996 478.700.000 5.35%
1997 494.700.000 3.23%
1998 616.800.000 19.8%
1999 682.400.000 9.61%
2000 822.700.000 17.05%
2001 925.600.000 11.12%
2002 1.061.800.000 12.83%
2003 1.224.600.000 13.29%
2004 1.289.300.000 5.02%
2005 1.390.300.000 7.26%
2006 1.529.400.000 9.1%
2007 1.691.200.000 9.57%
2008 1.873.800.000 9.74%
2009 1.970.900.000 4.93%
2010 2.097.800.000 6.05%
2011 2.274.700.000 7.78%
2012 2.249.700.000 -1.11%
2013 2.223.200.000 -1.19%
2014 2.203.100.000 -0.91%
2015 2.903.300.000 24.12%
2016 3.180.500.000 8.72%
2017 3.464.000.000 8.18%
2018 3.176.400.000 -9.05%
2019 3.252.500.000 2.34%
2020 4.952.800.000 34.33%
2021 5.624.300.000 11.94%
2022 4.385.100.000 -28.26%
2023 3.404.800.000 -28.79%
2023 3.145.100.000 -8.26%
2024 3.456.800.000 9.02%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Laboratory Corporation of America Holdings Net Profit
Year Net Profit Growth
1988 0
1989 64.700.000 100%
1990 82.600.000 21.67%
1991 103.900.000 20.5%
1992 40.600.000 -155.91%
1993 112.700.000 63.98%
1994 30.100.000 -274.42%
1995 -12.300.000 344.72%
1996 -153.500.000 91.99%
1997 -106.900.000 -43.59%
1998 68.800.000 255.38%
1999 65.400.000 -5.2%
2000 112.100.000 41.66%
2001 179.500.000 37.55%
2002 254.600.000 29.5%
2003 321.000.000 20.69%
2004 363.000.000 11.57%
2005 386.200.000 6.01%
2006 431.600.000 10.52%
2007 476.800.000 9.48%
2008 464.500.000 -2.65%
2009 543.300.000 14.5%
2010 558.200.000 2.67%
2011 519.700.000 -7.41%
2012 583.100.000 10.87%
2013 573.800.000 -1.62%
2014 511.200.000 -12.25%
2015 436.900.000 -17.01%
2016 732.100.000 40.32%
2017 1.268.200.000 42.27%
2018 883.700.000 -43.51%
2019 823.800.000 -7.27%
2020 1.556.100.000 47.06%
2021 2.377.300.000 34.54%
2022 1.279.100.000 -85.86%
2023 733.200.000 -74.45%
2023 418.000.000 -75.41%
2024 821.200.000 49.1%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Laboratory Corporation of America Holdings Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1988 1
1989 2 0%
1990 2 50%
1991 3 0%
1992 1 -100%
1993 3 66.67%
1994 1 0%
1995 0 0%
1996 -3 100%
1997 -2 -50%
1998 1 0%
1999 0 0%
2000 1 0%
2001 1 100%
2002 2 0%
2003 2 50%
2004 3 0%
2005 3 0%
2006 3 33.33%
2007 4 25%
2008 5 0%
2009 5 0%
2010 5 20%
2011 5 0%
2012 6 16.67%
2013 7 0%
2014 6 0%
2015 4 -50%
2016 7 42.86%
2017 12 41.67%
2018 9 -50%
2019 8 0%
2020 16 46.67%
2021 25 37.5%
2022 14 -71.43%
2023 8 -75%
2023 5 -100%
2024 10 55.56%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Laboratory Corporation of America Holdings Free Cashflow
Year Free Cashflow Growth
1989 48.100.000
1990 97.500.000 50.67%
1991 107.400.000 9.22%
1992 63.600.000 -68.87%
1993 23.600.000 -169.49%
1994 -34.200.000 169.01%
1995 -28.400.000 -20.42%
1996 -240.900.000 88.21%
1997 109.900.000 319.2%
1998 42.700.000 -157.38%
1999 111.100.000 61.57%
2000 191.200.000 41.89%
2001 227.900.000 16.1%
2002 370.600.000 38.51%
2003 480.700.000 22.9%
2004 443.100.000 -8.49%
2005 480.600.000 7.8%
2006 515.800.000 6.82%
2007 566.400.000 8.93%
2008 624.200.000 9.26%
2009 747.700.000 16.52%
2010 757.100.000 1.24%
2011 709.900.000 -6.65%
2012 665.100.000 -6.74%
2013 616.500.000 -7.88%
2014 535.500.000 -15.13%
2015 726.600.000 26.3%
2016 897.000.000 19%
2017 1.144.000.000 21.59%
2018 925.600.000 -23.6%
2019 1.044.500.000 11.38%
2020 1.753.600.000 40.44%
2021 2.649.200.000 33.81%
2022 1.474.000.000 -79.73%
2023 170.600.000 -764.01%
2023 874.100.000 80.48%
2024 432.900.001 -101.92%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Laboratory Corporation of America Holdings Operating Cashflow
Year Operating Cashflow Growth
1989 71.800.000
1990 112.400.000 36.12%
1991 134.000.000 16.12%
1992 100.800.000 -32.94%
1993 57.200.000 -76.22%
1994 14.700.000 -289.12%
1995 47.000.000 68.72%
1996 -186.800.000 125.16%
1997 144.400.000 229.36%
1998 125.100.000 -15.43%
1999 180.500.000 30.69%
2000 246.700.000 26.83%
2001 316.000.000 21.93%
2002 444.900.000 28.97%
2003 564.300.000 21.16%
2004 538.100.000 -4.87%
2005 574.200.000 6.29%
2006 632.300.000 9.19%
2007 709.700.000 10.91%
2008 780.900.000 9.12%
2009 862.400.000 9.45%
2010 883.600.000 2.4%
2011 855.600.000 -3.27%
2012 841.400.000 -1.69%
2013 818.700.000 -2.77%
2014 739.000.000 -10.78%
2015 982.400.000 24.78%
2016 1.175.900.000 16.46%
2017 1.459.400.000 19.43%
2018 1.305.400.000 -11.8%
2019 1.444.700.000 9.64%
2020 2.135.300.000 32.34%
2021 3.109.600.000 31.33%
2022 1.955.900.000 -58.99%
2023 275.500.000 -609.95%
2023 1.327.700.000 79.25%
2024 561.100.000 -136.62%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Laboratory Corporation of America Holdings Capital Expenditure
Year Capital Expenditure Growth
1989 23.700.000
1990 14.900.000 -59.06%
1991 26.600.000 43.98%
1992 37.200.000 28.49%
1993 33.600.000 -10.71%
1994 48.900.000 31.29%
1995 75.400.000 35.15%
1996 54.100.000 -39.37%
1997 34.500.000 -56.81%
1998 82.400.000 58.13%
1999 69.400.000 -18.73%
2000 55.500.000 -25.05%
2001 88.100.000 37%
2002 74.300.000 -18.57%
2003 83.600.000 11.12%
2004 95.000.000 12%
2005 93.600.000 -1.5%
2006 116.500.000 19.66%
2007 143.300.000 18.7%
2008 156.700.000 8.55%
2009 114.700.000 -36.62%
2010 126.500.000 9.33%
2011 145.700.000 13.18%
2012 176.300.000 17.36%
2013 202.200.000 12.81%
2014 203.500.000 0.64%
2015 255.800.000 20.45%
2016 278.900.000 8.28%
2017 315.400.000 11.57%
2018 379.800.000 16.96%
2019 400.200.000 5.1%
2020 381.700.000 -4.85%
2021 460.400.000 17.09%
2022 481.900.000 4.46%
2023 104.900.000 -359.39%
2023 453.600.000 76.87%
2024 128.199.999 -253.82%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Laboratory Corporation of America Holdings Equity
Year Equity Growth
1989 330.000.000
1990 256.700.000 -28.55%
1991 330.800.000 22.4%
1992 212.500.000 -55.67%
1993 140.800.000 -50.92%
1994 166.000.000 15.18%
1995 411.600.000 59.67%
1996 258.100.000 -59.47%
1997 630.000.000 59.03%
1998 681.200.000 7.52%
1999 734.200.000 7.22%
2000 877.400.000 16.32%
2001 1.085.400.000 19.16%
2002 1.611.700.000 32.65%
2003 1.895.900.000 14.99%
2004 1.999.300.000 5.17%
2005 1.885.700.000 -6.02%
2006 1.977.100.000 4.62%
2007 1.725.300.000 -14.59%
2008 1.789.600.000 3.59%
2009 2.248.500.000 20.41%
2010 2.635.000.000 14.67%
2011 2.523.700.000 -4.41%
2012 2.717.200.000 7.12%
2013 2.500.600.000 -8.66%
2014 2.838.200.000 11.89%
2015 5.025.200.000 43.52%
2016 5.521.000.000 8.98%
2017 6.850.800.000 19.41%
2018 6.990.500.000 2%
2019 7.587.100.000 7.86%
2020 9.380.400.000 19.12%
2021 10.293.500.000 8.87%
2022 10.115.500.000 -1.76%
2023 7.890.500.000 -28.2%
2023 7.892.500.000 0.03%
2024 8.020.800.000 1.6%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Laboratory Corporation of America Holdings Assets
Year Assets Growth
1989 368.200.000
1990 374.200.000 1.6%
1991 411.300.000 9.02%
1992 477.400.000 13.85%
1993 585.500.000 18.46%
1994 1.012.700.000 42.18%
1995 1.837.200.000 44.88%
1996 1.917.000.000 4.16%
1997 1.658.500.000 -15.59%
1998 1.640.900.000 -1.07%
1999 1.590.200.000 -3.19%
2000 1.666.900.000 4.6%
2001 1.929.600.000 13.61%
2002 2.611.800.000 26.12%
2003 3.414.900.000 23.52%
2004 3.600.900.000 5.17%
2005 3.875.800.000 7.09%
2006 4.000.800.000 3.12%
2007 4.368.200.000 8.41%
2008 4.669.500.000 6.45%
2009 4.859.500.000 3.91%
2010 6.187.800.000 21.47%
2011 6.171.000.000 -0.27%
2012 6.809.700.000 9.38%
2013 6.949.500.000 2.01%
2014 7.301.800.000 4.82%
2015 14.286.200.000 48.89%
2016 14.247.000.000 -0.28%
2017 16.568.000.000 14.01%
2018 16.185.300.000 -2.36%
2019 18.021.400.000 10.19%
2020 20.071.700.000 10.21%
2021 20.385.400.000 1.54%
2022 20.155.100.000 -1.14%
2023 16.725.099.999 -20.51%
2023 16.886.000.000 0.95%
2024 16.712.300.000 -1.04%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Laboratory Corporation of America Holdings Liabilities
Year Liabilities Growth
1989 38.200.000
1990 117.500.000 67.49%
1991 80.500.000 -45.96%
1992 264.900.000 69.61%
1993 444.700.000 40.43%
1994 846.700.000 47.48%
1995 1.425.600.000 40.61%
1996 1.658.900.000 14.06%
1997 1.028.500.000 -61.29%
1998 959.700.000 -7.17%
1999 856.000.000 -12.11%
2000 789.500.000 -8.42%
2001 844.200.000 6.48%
2002 1.000.100.000 15.59%
2003 1.519.000.000 34.16%
2004 1.601.600.000 5.16%
2005 1.990.100.000 19.52%
2006 2.023.700.000 1.66%
2007 2.642.900.000 23.43%
2008 2.879.900.000 8.23%
2009 2.611.000.000 -10.3%
2010 3.552.800.000 26.51%
2011 3.647.300.000 2.59%
2012 4.092.300.000 10.87%
2013 4.468.300.000 8.41%
2014 4.481.300.000 0.29%
2015 9.275.900.000 51.69%
2016 8.741.200.000 -6.12%
2017 9.738.000.000 10.24%
2018 9.213.900.000 -5.69%
2019 10.454.400.000 11.87%
2020 10.712.000.000 2.4%
2021 10.112.500.000 -5.93%
2022 10.058.500.000 -0.54%
2023 8.834.600.000 -13.85%
2023 8.993.500.000 1.77%
2024 8.691.500.000 -3.47%

Laboratory Corporation of America Holdings Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
148.49
Net Income per Share
5.34
Price to Earning Ratio
39.79x
Price To Sales Ratio
1.43x
POCF Ratio
12.9
PFCF Ratio
20.95
Price to Book Ratio
2.23
EV to Sales
1.89
EV Over EBITDA
13.4
EV to Operating CashFlow
17
EV to FreeCashFlow
27.65
Earnings Yield
0.03
FreeCashFlow Yield
0.05
Market Cap
17,86 Bil.
Enterprise Value
23,57 Bil.
Graham Number
106.99
Graham NetNet
-77.54

Income Statement Metrics

Net Income per Share
5.34
Income Quality
3.08
ROE
0.06
Return On Assets
0.03
Return On Capital Employed
0.09
Net Income per EBT
0.68
EBT Per Ebit
0.59
Ebit per Revenue
0.09
Effective Tax Rate
0.31

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0.01
Gross Profit Margin
0.27
Operating Profit Margin
0.09
Pretax Profit Margin
0.05
Net Profit Margin
0.04

Dividends

Dividend Yield
0.02
Dividend Yield %
1.69
Payout Ratio
0.55
Dividend Per Share
3.6

Operating Metrics

Operating Cashflow per Share
16.49
Free CashFlow per Share
10.13
Capex to Operating CashFlow
0.39
Capex to Revenue
0.04
Capex to Depreciation
0.88
Return on Invested Capital
0.06
Return on Tangible Assets
0.06
Days Sales Outstanding
65.66
Days Payables Outstanding
30.27
Days of Inventory on Hand
17.58
Receivables Turnover
5.56
Payables Turnover
12.06
Inventory Turnover
20.76
Capex per Share
6.35

Balance Sheet

Cash per Share
3,15
Book Value per Share
95,37
Tangible Book Value per Share
-18.21
Shareholders Equity per Share
95.19
Interest Debt per Share
64.79
Debt to Equity
0.66
Debt to Assets
0.31
Net Debt to EBITDA
3.25
Current Ratio
0.88
Tangible Asset Value
-1,53 Bil.
Net Current Asset Value
-5,12 Bil.
Invested Capital
11991300000
Working Capital
-0,49 Bil.
Intangibles to Total Assets
0.57
Average Receivables
2,23 Bil.
Average Payables
1,05 Bil.
Average Inventory
458400000
Debt to Market Cap
0.29

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Laboratory Corporation of America Holdings Dividends
Year Dividends Growth
1990 0
1991 0 0%
1992 0 0%
1993 0 0%
1994 0 0%
2022 2 100%
2023 3 0%
2024 3 0%

Laboratory Corporation of America Holdings Profile

About Laboratory Corporation of America Holdings

Laboratory Corporation of America Holdings operates as a global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). It offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C and vitamin D, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. The company also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases, including anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, and parentage and donor testing; and occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests. It provides online and mobile applications to enable patients to check test results; and online applications for managed care organizations and accountable care organizations. It offers end-to-end drug development, medical device, and companion diagnostic development solutions from early-stage research to clinical development and commercial market access. It serves managed care organizations, pharmaceutical, biotechnology, medical device and diagnostics companies, governmental agencies, physicians and other healthcare providers, hospitals and health systems, employers, patients and consumers, contract research organizations, and independent clinical laboratories. Laboratory Corporation of America Holdings has a collaboration agreement with Tigerlily Foundation to increase clinical trial diversity for women of color. The company was incorporated in 1994 and is headquartered in Burlington, North Carolina.

CEO
Mr. Adam H. Schechter
Employee
67.000
Address
358 South Main Street
Burlington, 27215

Laboratory Corporation of America Holdings Executives & BODs

Laboratory Corporation of America Holdings Executives & BODs
# Name Age
1 Mr. Adam H. Schechter
President, Chief Executive Officer & Chairman
70
2 Mr. Mark S. Schroeder
Executive Vice President, President of Diagnostics Laboratories & Chief Operating Officer
70
3 Dr. Brian J. Caveney J.D., M.D., M.P.H.
EVice President, President of Early Development Research Laboratories and Chief Medical & Scientific Officer
70
4 Ms. Anita Z. Graham
Executive Vice President & Chief Human Resources Officer
70
5 Mr. Peter J. Wilkinson
Senior Vice President & Chief Accounting Officer
70
6 Ms. Sandra D. van der Vaart J.D.
Executive Vice President, Chief Legal Officer & Corporate Secretary
70
7 Ms. Amy B. Summy
Executive Vice President & Chief Marketing Officer
70
8 Mr. Lance V. Berberian
Executive Vice President and Chief Information & Technology Officer
70
9 Christin O'Donnell
Vice President of Investor Relations
70
10 Mr. Glenn A. Eisenberg
Chief Financial Officer & Executive Vice President
70

Laboratory Corporation of America Holdings Competitors